Company
Renasantbio
Correctors and Potentiators for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Also known as Renasant Bio, Renasant Bio, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Berkeley, CA, United States
- Legal name
- Renasant Bio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
At Renasant Bio, we are pioneering a new approach to treating autosomal dominant polycystic kidney disease (ADPKD), a devastating genetic disorder with no disease-modifying therapies and the leading genetic cause of end-stage renal failure. Our mission is to develop small molecule correctors and potentiators that target the root cause of the disease, restoring the function of polycystin 1 and 2 (PC1/2) to halt disease progression.
Funding snapshot
- Total raised
- $55.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Seed, $54.5M2025-07-10
Funding rounds
- Seed
- $54.5M2025-07-10, Company stated
- Round, 2025
- $30M2025-06-03, SEC form D sold, 4 investors
- Round, 2024
- $25.5M2024-07-15, SEC form D sold, 3 investors
Products
- Web
- Correctors
- Web
- Potentiators
Loading relationship preview